相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development
Hitoshi Kiyoi et al.
CANCER SCIENCE (2020)
Glucocorticoids enhance the antileukemic activity of FLT3 inhibitors in FLT3-mutant acute myeloid leukemia
Melat T. Gebru et al.
BLOOD (2020)
Gilteritinib: potent targeting of FLT3 mutations in AML
Mark Levis et al.
BLOOD ADVANCES (2020)
Stem Cell Plasticity and Dormancy in the Development of Cancer Therapy Resistance
Maria Laura De Angelis et al.
FRONTIERS IN ONCOLOGY (2019)
Significance of FLT3-tyrosine kinase domain mutation as a prognostic factor for acute myeloid leukemia
Masahiro Sakaguchi et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2019)
Overcoming adaptive therapy resistance in AML by targeting immune response pathways
Katelyn Melgar et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML
A. E. Perl et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Dormant, quiescent, tolerant and persister cells: Four synonyms for the same target in cancer
Francois M. Vallette et al.
BIOCHEMICAL PHARMACOLOGY (2019)
Clinical implications of measurable residual disease in AML: Review of current evidence
Ine a Moors et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2019)
CD34+CD38- leukemic stem cell frequency to predict outcome in acute myeloid leukemia
Wendelien Zeijlemaker et al.
LEUKEMIA (2019)
Targeting FLT3 mutations in AML: review of current knowledge and evidence
Naval Daver et al.
LEUKEMIA (2019)
Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms
Haijiao Zhang et al.
NATURE COMMUNICATIONS (2019)
Isocitrate dehydrogenase inhibitors in acute myeloid leukemia
Xiaoyan Liu et al.
BIOMARKER RESEARCH (2019)
Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia
Juanjuan Zhao et al.
BIOMARKER RESEARCH (2019)
Gilteritinib induces differentiation in relapsed and refractory FLT3-mutated acute myeloid leukemia
Christine M. McMahon et al.
BLOOD ADVANCES (2019)
Hematopoietic cytokines mediate resistance to targeted therapy in FLT3-ITD acute myeloid leukemia
Pamela J. Sung et al.
BLOOD ADVANCES (2019)
Role of CYP3A4 in bone marrow microenvironment-mediated protection of FLT3/ITD AML from tyrosine kinase inhibitors
Yu-Ting Chang et al.
BLOOD ADVANCES (2019)
Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations
Andrew M. Intlekofer et al.
NATURE (2018)
Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis
Richard M. Stone et al.
BLOOD ADVANCES (2018)
PIM Kinase as an Executional Target in Cancer
Xinning Zhang et al.
JOURNAL OF CANCER PREVENTION (2018)
FLT3 and FLT3-ITD phosphorylate and inactivate the cyclin-dependent kinase inhibitor p27Kip1 in acute myeloid leukemia
Ines Peschel et al.
HAEMATOLOGICA (2017)
Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia
Masamichi Mori et al.
INVESTIGATIONAL NEW DRUGS (2017)
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study
Alexander E. Perl et al.
LANCET ONCOLOGY (2017)
FLT3-ITD and its current role in acute myeloid leukaemia
Francisco Alejandro Lagunas-Rangel et al.
MEDICAL ONCOLOGY (2017)
FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions
Maria Larrosa-Garcia et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Tracing the origins of relapse in acute myeloid leukaemia to stem cells
Liran I. Shlush et al.
NATURE (2017)
Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition
Matthew J. Hangauer et al.
NATURE (2017)
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
R. M. Stone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Recurrent Tumor Cell-Intrinsic and -Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation
Chunying Song et al.
CANCER DISCOVERY (2017)
The Future of Targeting FLT3 Activation in AML
Mark B. Leick et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2017)
FLT3 and FLT3-ITD phosphorylate and inactivate the cyclin-dependent kinase inhibitor p27Kip1 in acute myeloid leukemia
Ines Peschel et al.
HAEMATOLOGICA (2017)
Midostaurin: a novel therapeutic agent for patients with FLT3-mutated acute myeloid leukemia and systemic mastocytosis
Molly M. Gallogly et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2017)
FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia
Elie Traer et al.
CANCER RESEARCH (2016)
Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition
Aaron N. Hata et al.
NATURE MEDICINE (2016)
Assessment of Minimal Residual Disease in Standard-Risk AML
A. Ivey et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Genomic Classification and Prognosis in Acute Myeloid Leukemia
Elli Papaemmanuil et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Functional screening implicates miR-371-3p and peroxiredoxin 6 in reversible tolerance to cancer drugs
Nisebita Sahu et al.
NATURE COMMUNICATIONS (2016)
Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells
Michael Ramirez et al.
NATURE COMMUNICATIONS (2016)
Acute myeloid leukemia: a comprehensive review and 2016 update
I. De Kouchkovsky et al.
BLOOD CANCER JOURNAL (2016)
Mutations in AML: prognostic and therapeutic implications
Courtney D. DiNardo et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2016)
MRD in AML: does it already guide therapy decision-making?
Gert Ossenkoppele et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2016)
Acute Myeloid Leukemia: A Concise Review
Jennifer N. Saultz et al.
JOURNAL OF CLINICAL MEDICINE (2016)
A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations
Walter Fiedler et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors
C. C. Smith et al.
LEUKEMIA (2015)
Therapy-induced tumour secretomes promote resistance and tumour progression
Anna C. Obenauf et al.
NATURE (2015)
Acute Myeloid Leukemia
Hartmut Doehner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 Gatekeeper F691L Mutation with PLX3397
Catherine C. Smith et al.
CANCER DISCOVERY (2015)
Targeting the Microenvironment in Acute Myeloid Leukemia
Armin Rashidi et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2015)
Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia
Alexa S. Green et al.
SCIENCE ADVANCES (2015)
Targeting cell cycle regulators in hematologic malignancies
Eiman Aleem et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2015)
Bone marrow stroma-mediated resistance to FLT3 inhibitors in FLT3-ITD AML is mediated by persistent activation of extracellular regulated kinase
Xiaochuan Yang et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Treatment With FLT3 Inhibitor in Patients With FLT3-Mutated Acute Myeloid Leukemia Is Associated With Development of Secondary FLT3-Tyrosine Kinase Domain Mutations
Yesid Alvarado et al.
CANCER (2014)
The biology and targeting of FLT3 in pediatric leukemia
Colleen E. Annesley et al.
FRONTIERS IN ONCOLOGY (2014)
Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD
Catherine C. Smith et al.
BLOOD (2013)
Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia
Jan Kroenke et al.
BLOOD (2013)
Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD-Positive Acute Myeloid Leukemia
Sharyn D. Baker et al.
CLINICAL CANCER RESEARCH (2013)
Pim-1 Kinase Phosphorylates and Stabilizes 130 kDa FLT3 and Promotes Aberrant STAT5 Signaling in Acute Myeloid Leukemia with FLT3 Internal Tandem Duplication
Karthika Natarajan et al.
PLOS ONE (2013)
Genetic Ablation of Epidermal EGFR Reveals the Dynamic Origin of Adverse Effects of Anti-EGFR Therapy
Francesca Mascia et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITDAML
Amy Sexauer et al.
BLOOD (2012)
Sorafenib treatment of FLT3-ITD+ acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation
Cheuk Him Man et al.
BLOOD (2012)
Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas
Piro Lito et al.
CANCER CELL (2012)
Drug resistance: Still a daunting challenge to the successful treatment of AML
Brian C. Shaffer et al.
DRUG RESISTANCE UPDATES (2012)
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
Catherine C. Smith et al.
NATURE (2012)
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing
Li Ding et al.
NATURE (2012)
An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment
Tiziana Grafone et al.
ONCOLOGY REVIEWS (2012)
Stochastic State Transitions Give Rise to Phenotypic Equilibrium in Populations of Cancer Cells
Piyush B. Gupta et al.
CELL (2011)
Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications
Shinichiro Takahashi
JOURNAL OF HEMATOLOGY & ONCOLOGY (2011)
Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state
Christine L. Chaffer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Differential signaling of Flt3 activating mutations in acute myeloid leukemia: a working model
Perry M. Chan
PROTEIN & CELL (2011)
Mechanisms of resistance against PKC412 in resistant FLT3-ITD positive human acute myeloid leukemia cells
Friedrich Stoelzel et al.
ANNALS OF HEMATOLOGY (2010)
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sreenath V. Sharma et al.
CELL (2010)
Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3
Thomas Fischer et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AML
Frank Breitenbuecher et al.
BLOOD (2009)
Anchoring of FLT3 in the endoplasmic reticulum alters signaling quality
Dirk Schmidt-Arras et al.
BLOOD (2009)
Structural and Functional Alterations of FLT3 in Acute Myeloid Leukemia
Soheil Meshinchi et al.
CLINICAL CANCER RESEARCH (2009)
Internal tandem duplication of FLT3 (FLT3/ITD) induces increased ROS production, DNA damage, and misrepair: implications for poor prognosis in AML
Annahita Sallmyr et al.
BLOOD (2008)
Deregulation of signaling pathways in acute myeloid leukemia
Claudia Scholl et al.
SEMINARS IN ONCOLOGY (2008)
Prognostic relevance of FLT3-TKD mutations in AML:: the combination matters -: an analysis of 3082 patients
Ulrike Bacher et al.
BLOOD (2008)
FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia
Adam J. Mead et al.
BLOOD (2007)
Flt3-dependent transformation by inactivating c-Cbl mutations in AML
Buelent Sargin et al.
BLOOD (2007)
Activation mechanisms of STAT5 by oncogenic Flt3-ITD
Chunaram Choudhary et al.
BLOOD (2007)
Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways
Obdulio Piloto et al.
BLOOD (2007)
Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITD
Jennifer L. Rocnik et al.
BLOOD (2006)
Inhibition of the MEK/MAPK signal transduction pathway strongly impairs the growth of Flt3-ITD cells
S Takahashi
AMERICAN JOURNAL OF HEMATOLOGY (2006)
Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain
F Heidel et al.
BLOOD (2006)
Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myelold transformation
CH Brandts et al.
CANCER RESEARCH (2005)
The molecular pathogenesis of acute myeloid leukemia
B Steffen et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2005)
Acute myeloid leukaemia with FLT3 gene mutations of both internal tandem duplication and point mutation type
WN Chen et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3
M Martin et al.
NATURE IMMUNOLOGY (2005)
The structural basis for autoinhibition of FLT3 by the juxtamembrane domain
J Griffith et al.
MOLECULAR CELL (2004)
The expression of P-glycoprotein in AML cells with FLT3 internal tandem duplications is associated with reduced apoptosis in response to FLT3 inhibitors
HM Hunter et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
The role of FLT3 in haematopoietic malignancies
DL Stirewalt et al.
NATURE REVIEWS CANCER (2003)
Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation
F Mascia et al.
AMERICAN JOURNAL OF PATHOLOGY (2003)
Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia:: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse
LY Shih et al.
BLOOD (2002)
Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412
E Weisberg et al.
CANCER CELL (2002)
Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C
DJ Propper et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
分享论文
